Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Diseas

First analysis data from CARTITUDE-4 demonstrated a statistically significant improvement in progression-free survival, with a hazard ratio of 0.26



CARTITUDE-4 is the first randomized study... | June 5, 2023

Related Keywords

Japan , China , New Jersey , United States , American , Hemophagocytic Lymphohistiocytosis , European Hematology Association , Janssen Biotech Inc , Medicinal Devices Agency , Legend Biotech Corporation , American Society Of Clinical Oncology , Exchange Commission On , Drug Administration , Linkedin , Community Register Of Orphan Medicinal Products , Japan Ministry Of Health , American Society Of Oncology Annual Meeting , Congress Abstract , European Commission , Twitter , American Cancer Society , European Commission For The Treatment Of Patients , Legend Biotech , New England Journal , Hematology Association , Hybrid Congress , Demonstrated Deep , Year Follow Up Data , Janssen Biotech , Important Safety , Release Syndrome , Effector Cell Associated Neurotoxicity Syndrome , Macrophage Activation Syndrome , Risk Evaluation , Mitigation Strategy , Nerve Palsies , Recurrent Cytopenias , Igg Hypersensitivity Reactions , Use Machines , Prescribing Information , Boxed Warning , Breakthrough Therapy Designation , Orphan Drug Designation , European Medicines Agency , Orphan Medicinal Products , Private Securities Litigation Reform Act , Annual Report , Exchange Commission , Oncology Annual Meeting , Long Term Remission , Refractory Multiple Myeloma After Treatment , Year Follow Up , Adult Patients , Refractory Multiple , Accessed October , Granted Conditional Approval , Receives Approval , Community Register , Orphan Medicinal , Statistics About Multiple Myeloma , Accessed January , Legend Biotech Corporation Stock Exchange , News , Information , Press Release , First , Analysis , Data , Rom , Remonstrated , Statistically , Significant , Improvement , N , Ith , Hazard , Patio , F , Us , The , Andomized Legn Us52490g1022 ,